M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn Pharmaceutical TechnologyGilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.Read full story pharminent May 22, 2026 (Last updated: May 22, 2026) Pharmaceutical Technology Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn. Read full story Post navigation Previous: In Alzheimer’s, Bristol Myers sees big promise beyond amyloidNext: GBL joins CVC in 10.7bn takeover bid for Recordati Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026